Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK2 | Q13002 | 3/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984730 | 0.91 | GRIK2 (0.49) | GRIK2GRIK1ESR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL10193447 | 0.90 | GRIK2 (0.42) | GRIK2GRIK1ESR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL10193452 | 0.89 | GRIK2 (0.41) | GRIK2GRIK1ESR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL10193446 | 0.89 | GRIK2 (0.41) | GRIK2GRIK1ESR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL10193531 | 0.89 | GRIK2 (0.44) | GRIK2GRIK1ESR1L3MBTL1LMNA | |
| SCHEMBL10096632 | 0.87 | GRIK2 (0.40) | GRIK2GRIK1ESR1L3MBTL1LMNA | |
| SCHEMBL10097238 | 0.84 | GRIK2 (0.56) | GRIK2GRIK1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL10193460 | 0.83 | GRIK2 (0.37) | GRIK2GRIK1ESR1L3MBTL1ALDH1A1 | |
| SCHEMBL10193451 | 0.83 | ALDH1A1 (0.42) | GRIK2GRIK1ESR1SMN1; SMN2HTT | |
| SCHEMBL10193457 | 0.83 | MTNR1A (0.43) | ESR1L3MBTL1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | GRIK2 3701/4885GRIK1 3372/4885ESR1 2188/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | GRIK2 4399/4885GRIK1 4352/4885ESR1 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.